nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—prostate cancer—urinary bladder cancer	0.78	1	CtDrD
Bicalutamide—CYP3A4—Thiotepa—urinary bladder cancer	0.0128	0.36	CbGbCtD
Bicalutamide—AR—scrotum—urinary bladder cancer	0.0112	0.317	CbGeAlD
Bicalutamide—CYP2C9—Fluorouracil—urinary bladder cancer	0.00715	0.201	CbGbCtD
Bicalutamide—CYP2C9—Cisplatin—urinary bladder cancer	0.00607	0.171	CbGbCtD
Bicalutamide—AR—penis—urinary bladder cancer	0.00506	0.143	CbGeAlD
Bicalutamide—CYP2D6—Doxorubicin—urinary bladder cancer	0.00372	0.105	CbGbCtD
Bicalutamide—CYP3A4—Etoposide—urinary bladder cancer	0.00347	0.0975	CbGbCtD
Bicalutamide—CYP2C19—urine—urinary bladder cancer	0.00312	0.0882	CbGeAlD
Bicalutamide—CYP2C9—urine—urinary bladder cancer	0.00242	0.0684	CbGeAlD
Bicalutamide—CYP3A4—Doxorubicin—urinary bladder cancer	0.00237	0.0665	CbGbCtD
Bicalutamide—CYP3A4—urine—urinary bladder cancer	0.00184	0.0521	CbGeAlD
Bicalutamide—CYP2D6—urine—urinary bladder cancer	0.00181	0.0513	CbGeAlD
Bicalutamide—AR—prostate gland—urinary bladder cancer	0.00121	0.0342	CbGeAlD
Bicalutamide—AR—seminal vesicle—urinary bladder cancer	0.00102	0.0289	CbGeAlD
Bicalutamide—AR—epithelium—urinary bladder cancer	0.000887	0.0251	CbGeAlD
Bicalutamide—AR—smooth muscle tissue—urinary bladder cancer	0.000855	0.0242	CbGeAlD
Bicalutamide—AR—renal system—urinary bladder cancer	0.000823	0.0233	CbGeAlD
Bicalutamide—AR—urethra—urinary bladder cancer	0.000809	0.0229	CbGeAlD
Bicalutamide—AR—female reproductive system—urinary bladder cancer	0.000659	0.0187	CbGeAlD
Bicalutamide—AR—vagina—urinary bladder cancer	0.000596	0.0169	CbGeAlD
Bicalutamide—CYP2C19—vagina—urinary bladder cancer	0.000552	0.0156	CbGeAlD
Bicalutamide—CYP2C9—female reproductive system—urinary bladder cancer	0.000474	0.0134	CbGeAlD
Bicalutamide—CYP3A4—renal system—urinary bladder cancer	0.000451	0.0128	CbGeAlD
Bicalutamide—CYP2D6—renal system—urinary bladder cancer	0.000444	0.0126	CbGeAlD
Bicalutamide—AR—lymph node—urinary bladder cancer	0.000386	0.0109	CbGeAlD
Bicalutamide—CYP3A4—female reproductive system—urinary bladder cancer	0.000361	0.0102	CbGeAlD
Bicalutamide—CYP2D6—female reproductive system—urinary bladder cancer	0.000355	0.0101	CbGeAlD
Bicalutamide—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000112	0.00355	CbGpPWpGaD
Bicalutamide—AR—Nongenotropic Androgen signaling—HRAS—urinary bladder cancer	0.000111	0.00353	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—urinary bladder cancer	0.000111	0.00353	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—CREBBP—urinary bladder cancer	0.000111	0.00352	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00011	0.00351	CbGpPWpGaD
Bicalutamide—AR—Regulation of Androgen receptor activity—EP300—urinary bladder cancer	0.000106	0.00336	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000105	0.00333	CbGpPWpGaD
Bicalutamide—AR—Regulation of Androgen receptor activity—SRC—urinary bladder cancer	0.000103	0.00327	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000103	0.00327	CbGpPWpGaD
Bicalutamide—AR—Coregulation of Androgen receptor activity—CCND1—urinary bladder cancer	0.000103	0.00326	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—CREBBP—urinary bladder cancer	0.000103	0.00326	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—RB1—urinary bladder cancer	0.000102	0.00325	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000102	0.00324	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000102	0.00322	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000101	0.0032	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—urinary bladder cancer	9.8e-05	0.00311	CbGpPWpGaD
Bicalutamide—CYP2C19—Arachidonic acid metabolism—GPX1—urinary bladder cancer	9.47e-05	0.003	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—RHOA—urinary bladder cancer	9.29e-05	0.00295	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—urinary bladder cancer	8.89e-05	0.00282	CbGpPWpGaD
Bicalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	8.79e-05	0.00279	CbGpPWpGaD
Bicalutamide—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	8.63e-05	0.00274	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	8.62e-05	0.00274	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	8.5e-05	0.0027	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	8.35e-05	0.00265	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—urinary bladder cancer	8.28e-05	0.00263	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	8.2e-05	0.0026	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	8.17e-05	0.0026	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	8.17e-05	0.0026	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	8.06e-05	0.00256	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—urinary bladder cancer	8.04e-05	0.00255	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—CDKN1A—urinary bladder cancer	7.93e-05	0.00252	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—ATM—urinary bladder cancer	7.74e-05	0.00246	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CDK4—urinary bladder cancer	7.71e-05	0.00245	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—ESR1—urinary bladder cancer	7.68e-05	0.00244	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—urinary bladder cancer	7.62e-05	0.00242	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—CCND1—urinary bladder cancer	7.6e-05	0.00241	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—EP300—urinary bladder cancer	7.54e-05	0.0024	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	7.48e-05	0.00237	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—NAT2—urinary bladder cancer	7.45e-05	0.00236	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	7.37e-05	0.00234	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—CDKN1A—urinary bladder cancer	7.35e-05	0.00233	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—NAT2—urinary bladder cancer	7.35e-05	0.00233	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—PTEN—urinary bladder cancer	7.34e-05	0.00233	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	7.26e-05	0.00231	CbGpPWpGaD
Bicalutamide—Urinary tract infection—Epirubicin—urinary bladder cancer	7.08e-05	0.0006	CcSEcCtD
Bicalutamide—Dysuria—Doxorubicin—urinary bladder cancer	7.07e-05	0.000599	CcSEcCtD
Bicalutamide—Neutropenia—Doxorubicin—urinary bladder cancer	7.07e-05	0.000599	CcSEcCtD
Bicalutamide—Hypersensitivity—Fluorouracil—urinary bladder cancer	7.03e-05	0.000596	CcSEcCtD
Bicalutamide—Haemoglobin—Methotrexate—urinary bladder cancer	7.02e-05	0.000595	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—EP300—urinary bladder cancer	7e-05	0.00222	CbGpPWpGaD
Bicalutamide—Haemorrhage—Methotrexate—urinary bladder cancer	6.99e-05	0.000592	CcSEcCtD
Bicalutamide—Sweating—Epirubicin—urinary bladder cancer	6.98e-05	0.000592	CcSEcCtD
Bicalutamide—Pollakiuria—Doxorubicin—urinary bladder cancer	6.98e-05	0.000592	CcSEcCtD
Bicalutamide—Asthenia—Gemcitabine—urinary bladder cancer	6.96e-05	0.00059	CcSEcCtD
Bicalutamide—Haematuria—Epirubicin—urinary bladder cancer	6.94e-05	0.000588	CcSEcCtD
Bicalutamide—Pharyngitis—Methotrexate—urinary bladder cancer	6.93e-05	0.000587	CcSEcCtD
Bicalutamide—Urinary tract disorder—Methotrexate—urinary bladder cancer	6.9e-05	0.000585	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Epirubicin—urinary bladder cancer	6.89e-05	0.000584	CcSEcCtD
Bicalutamide—Weight increased—Doxorubicin—urinary bladder cancer	6.88e-05	0.000583	CcSEcCtD
Bicalutamide—Epistaxis—Epirubicin—urinary bladder cancer	6.87e-05	0.000582	CcSEcCtD
Bicalutamide—Pruritus—Gemcitabine—urinary bladder cancer	6.86e-05	0.000582	CcSEcCtD
Bicalutamide—Nausea—Thiotepa—urinary bladder cancer	6.85e-05	0.000581	CcSEcCtD
Bicalutamide—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	6.85e-05	0.00217	CbGpPWpGaD
Bicalutamide—Urethral disorder—Methotrexate—urinary bladder cancer	6.85e-05	0.00058	CcSEcCtD
Bicalutamide—Weight decreased—Doxorubicin—urinary bladder cancer	6.84e-05	0.000579	CcSEcCtD
Bicalutamide—Sinusitis—Epirubicin—urinary bladder cancer	6.83e-05	0.000579	CcSEcCtD
Bicalutamide—Feeling abnormal—Etoposide—urinary bladder cancer	6.83e-05	0.000579	CcSEcCtD
Bicalutamide—Hyperglycaemia—Doxorubicin—urinary bladder cancer	6.82e-05	0.000578	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—SRC—urinary bladder cancer	6.8e-05	0.00216	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	6.79e-05	0.00216	CbGpPWpGaD
Bicalutamide—Pneumonia—Doxorubicin—urinary bladder cancer	6.78e-05	0.000574	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Etoposide—urinary bladder cancer	6.78e-05	0.000574	CcSEcCtD
Bicalutamide—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	6.76e-05	0.00214	CbGpPWpGaD
Bicalutamide—Pruritus—Fluorouracil—urinary bladder cancer	6.75e-05	0.000572	CcSEcCtD
Bicalutamide—Visual impairment—Methotrexate—urinary bladder cancer	6.73e-05	0.00057	CcSEcCtD
Bicalutamide—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	6.73e-05	0.00214	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—RB1—urinary bladder cancer	6.71e-05	0.00213	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	6.7e-05	0.00213	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CDH1—urinary bladder cancer	6.68e-05	0.00212	CbGpPWpGaD
Bicalutamide—Hypersensitivity—Cisplatin—urinary bladder cancer	6.66e-05	0.000565	CcSEcCtD
Bicalutamide—Bradycardia—Epirubicin—urinary bladder cancer	6.66e-05	0.000564	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—urinary bladder cancer	6.64e-05	0.00211	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	6.64e-05	0.00211	CbGpPWpGaD
Bicalutamide—Diarrhoea—Gemcitabine—urinary bladder cancer	6.64e-05	0.000563	CcSEcCtD
Bicalutamide—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	6.6e-05	0.00056	CcSEcCtD
Bicalutamide—Urticaria—Etoposide—urinary bladder cancer	6.58e-05	0.000558	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	6.57e-05	0.00209	CbGpPWpGaD
Bicalutamide—Haemoglobin—Epirubicin—urinary bladder cancer	6.57e-05	0.000557	CcSEcCtD
Bicalutamide—Jaundice—Doxorubicin—urinary bladder cancer	6.57e-05	0.000557	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	6.56e-05	0.00208	CbGpPWpGaD
Bicalutamide—Rhinitis—Epirubicin—urinary bladder cancer	6.55e-05	0.000555	CcSEcCtD
Bicalutamide—Abdominal pain—Etoposide—urinary bladder cancer	6.55e-05	0.000555	CcSEcCtD
Bicalutamide—Body temperature increased—Etoposide—urinary bladder cancer	6.55e-05	0.000555	CcSEcCtD
Bicalutamide—Conjunctivitis—Doxorubicin—urinary bladder cancer	6.55e-05	0.000555	CcSEcCtD
Bicalutamide—Urinary tract infection—Doxorubicin—urinary bladder cancer	6.55e-05	0.000555	CcSEcCtD
Bicalutamide—Haemorrhage—Epirubicin—urinary bladder cancer	6.54e-05	0.000554	CcSEcCtD
Bicalutamide—Diarrhoea—Fluorouracil—urinary bladder cancer	6.53e-05	0.000553	CcSEcCtD
Bicalutamide—Asthenia—Cisplatin—urinary bladder cancer	6.49e-05	0.00055	CcSEcCtD
Bicalutamide—Pharyngitis—Epirubicin—urinary bladder cancer	6.49e-05	0.00055	CcSEcCtD
Bicalutamide—Cardiac disorder—Methotrexate—urinary bladder cancer	6.48e-05	0.000549	CcSEcCtD
Bicalutamide—Sweating—Doxorubicin—urinary bladder cancer	6.46e-05	0.000547	CcSEcCtD
Bicalutamide—Urinary tract disorder—Epirubicin—urinary bladder cancer	6.46e-05	0.000547	CcSEcCtD
Bicalutamide—Oedema peripheral—Epirubicin—urinary bladder cancer	6.44e-05	0.000546	CcSEcCtD
Bicalutamide—Haematuria—Doxorubicin—urinary bladder cancer	6.42e-05	0.000544	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	6.42e-05	0.00204	CbGpPWpGaD
Bicalutamide—Urethral disorder—Epirubicin—urinary bladder cancer	6.41e-05	0.000543	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	6.39e-05	0.00203	CbGpPWpGaD
Bicalutamide—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	6.37e-05	0.00054	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	6.36e-05	0.00202	CbGpPWpGaD
Bicalutamide—Epistaxis—Doxorubicin—urinary bladder cancer	6.36e-05	0.000539	CcSEcCtD
Bicalutamide—Angiopathy—Methotrexate—urinary bladder cancer	6.34e-05	0.000537	CcSEcCtD
Bicalutamide—Sinusitis—Doxorubicin—urinary bladder cancer	6.32e-05	0.000536	CcSEcCtD
Bicalutamide—Immune system disorder—Methotrexate—urinary bladder cancer	6.31e-05	0.000535	CcSEcCtD
Bicalutamide—Dizziness—Fluorouracil—urinary bladder cancer	6.31e-05	0.000535	CcSEcCtD
Bicalutamide—Visual impairment—Epirubicin—urinary bladder cancer	6.3e-05	0.000534	CcSEcCtD
Bicalutamide—Mediastinal disorder—Methotrexate—urinary bladder cancer	6.3e-05	0.000533	CcSEcCtD
Bicalutamide—Chills—Methotrexate—urinary bladder cancer	6.27e-05	0.000531	CcSEcCtD
Bicalutamide—Diarrhoea—Cisplatin—urinary bladder cancer	6.19e-05	0.000524	CcSEcCtD
Bicalutamide—Alopecia—Methotrexate—urinary bladder cancer	6.17e-05	0.000523	CcSEcCtD
Bicalutamide—Vomiting—Gemcitabine—urinary bladder cancer	6.17e-05	0.000523	CcSEcCtD
Bicalutamide—Bradycardia—Doxorubicin—urinary bladder cancer	6.16e-05	0.000522	CcSEcCtD
Bicalutamide—Mental disorder—Methotrexate—urinary bladder cancer	6.12e-05	0.000519	CcSEcCtD
Bicalutamide—Rash—Gemcitabine—urinary bladder cancer	6.12e-05	0.000518	CcSEcCtD
Bicalutamide—Dermatitis—Gemcitabine—urinary bladder cancer	6.11e-05	0.000518	CcSEcCtD
Bicalutamide—Hypersensitivity—Etoposide—urinary bladder cancer	6.1e-05	0.000517	CcSEcCtD
Bicalutamide—Malnutrition—Methotrexate—urinary bladder cancer	6.08e-05	0.000515	CcSEcCtD
Bicalutamide—Haemoglobin—Doxorubicin—urinary bladder cancer	6.08e-05	0.000515	CcSEcCtD
Bicalutamide—Headache—Gemcitabine—urinary bladder cancer	6.08e-05	0.000515	CcSEcCtD
Bicalutamide—Cardiac disorder—Epirubicin—urinary bladder cancer	6.07e-05	0.000514	CcSEcCtD
Bicalutamide—Vomiting—Fluorouracil—urinary bladder cancer	6.07e-05	0.000514	CcSEcCtD
Bicalutamide—Rhinitis—Doxorubicin—urinary bladder cancer	6.06e-05	0.000514	CcSEcCtD
Bicalutamide—Haemorrhage—Doxorubicin—urinary bladder cancer	6.05e-05	0.000513	CcSEcCtD
Bicalutamide—Rash—Fluorouracil—urinary bladder cancer	6.02e-05	0.00051	CcSEcCtD
Bicalutamide—Dermatitis—Fluorouracil—urinary bladder cancer	6.01e-05	0.000509	CcSEcCtD
Bicalutamide—Pharyngitis—Doxorubicin—urinary bladder cancer	6e-05	0.000509	CcSEcCtD
Bicalutamide—Headache—Fluorouracil—urinary bladder cancer	5.98e-05	0.000506	CcSEcCtD
Bicalutamide—Urinary tract disorder—Doxorubicin—urinary bladder cancer	5.97e-05	0.000506	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—EGFR—urinary bladder cancer	5.96e-05	0.00189	CbGpPWpGaD
Bicalutamide—Oedema peripheral—Doxorubicin—urinary bladder cancer	5.96e-05	0.000505	CcSEcCtD
Bicalutamide—CYP2C19—Biological oxidations—HPGDS—urinary bladder cancer	5.95e-05	0.00189	CbGpPWpGaD
Bicalutamide—Asthenia—Etoposide—urinary bladder cancer	5.94e-05	0.000504	CcSEcCtD
Bicalutamide—Angiopathy—Epirubicin—urinary bladder cancer	5.93e-05	0.000503	CcSEcCtD
Bicalutamide—Urethral disorder—Doxorubicin—urinary bladder cancer	5.93e-05	0.000502	CcSEcCtD
Bicalutamide—Immune system disorder—Epirubicin—urinary bladder cancer	5.9e-05	0.0005	CcSEcCtD
Bicalutamide—Mediastinal disorder—Epirubicin—urinary bladder cancer	5.89e-05	0.000499	CcSEcCtD
Bicalutamide—Back pain—Methotrexate—urinary bladder cancer	5.88e-05	0.000498	CcSEcCtD
Bicalutamide—Chills—Epirubicin—urinary bladder cancer	5.87e-05	0.000497	CcSEcCtD
Bicalutamide—Pruritus—Etoposide—urinary bladder cancer	5.86e-05	0.000497	CcSEcCtD
Bicalutamide—Arrhythmia—Epirubicin—urinary bladder cancer	5.84e-05	0.000495	CcSEcCtD
Bicalutamide—Visual impairment—Doxorubicin—urinary bladder cancer	5.83e-05	0.000494	CcSEcCtD
Bicalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	5.8e-05	0.00184	CbGpPWpGaD
Bicalutamide—Alopecia—Epirubicin—urinary bladder cancer	5.78e-05	0.00049	CcSEcCtD
Bicalutamide—CYP2C19—Biological oxidations—GSTT1—urinary bladder cancer	5.78e-05	0.00183	CbGpPWpGaD
Bicalutamide—Nausea—Gemcitabine—urinary bladder cancer	5.76e-05	0.000488	CcSEcCtD
Bicalutamide—Vomiting—Cisplatin—urinary bladder cancer	5.75e-05	0.000487	CcSEcCtD
Bicalutamide—Mental disorder—Epirubicin—urinary bladder cancer	5.73e-05	0.000485	CcSEcCtD
Bicalutamide—Rash—Cisplatin—urinary bladder cancer	5.7e-05	0.000483	CcSEcCtD
Bicalutamide—Dermatitis—Cisplatin—urinary bladder cancer	5.7e-05	0.000483	CcSEcCtD
Bicalutamide—Malnutrition—Epirubicin—urinary bladder cancer	5.69e-05	0.000482	CcSEcCtD
Bicalutamide—Diarrhoea—Etoposide—urinary bladder cancer	5.67e-05	0.00048	CcSEcCtD
Bicalutamide—Nausea—Fluorouracil—urinary bladder cancer	5.67e-05	0.00048	CcSEcCtD
Bicalutamide—Anaemia—Methotrexate—urinary bladder cancer	5.62e-05	0.000476	CcSEcCtD
Bicalutamide—Cardiac disorder—Doxorubicin—urinary bladder cancer	5.61e-05	0.000476	CcSEcCtD
Bicalutamide—Flatulence—Epirubicin—urinary bladder cancer	5.61e-05	0.000475	CcSEcCtD
Bicalutamide—Tension—Epirubicin—urinary bladder cancer	5.58e-05	0.000473	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	5.58e-05	0.00177	CbGpPWpGaD
Bicalutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	5.57e-05	0.00177	CbGpPWpGaD
Bicalutamide—Nervousness—Epirubicin—urinary bladder cancer	5.53e-05	0.000468	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	5.51e-05	0.00175	CbGpPWpGaD
Bicalutamide—Back pain—Epirubicin—urinary bladder cancer	5.5e-05	0.000466	CcSEcCtD
Bicalutamide—Angiopathy—Doxorubicin—urinary bladder cancer	5.49e-05	0.000465	CcSEcCtD
Bicalutamide—Dizziness—Etoposide—urinary bladder cancer	5.48e-05	0.000464	CcSEcCtD
Bicalutamide—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	5.48e-05	0.00174	CbGpPWpGaD
Bicalutamide—Muscle spasms—Epirubicin—urinary bladder cancer	5.47e-05	0.000464	CcSEcCtD
Bicalutamide—Immune system disorder—Doxorubicin—urinary bladder cancer	5.46e-05	0.000463	CcSEcCtD
Bicalutamide—Mediastinal disorder—Doxorubicin—urinary bladder cancer	5.45e-05	0.000462	CcSEcCtD
Bicalutamide—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	5.43e-05	0.00172	CbGpPWpGaD
Bicalutamide—Chills—Doxorubicin—urinary bladder cancer	5.43e-05	0.00046	CcSEcCtD
Bicalutamide—Arrhythmia—Doxorubicin—urinary bladder cancer	5.4e-05	0.000458	CcSEcCtD
Bicalutamide—Nausea—Cisplatin—urinary bladder cancer	5.37e-05	0.000455	CcSEcCtD
Bicalutamide—Alopecia—Doxorubicin—urinary bladder cancer	5.35e-05	0.000453	CcSEcCtD
Bicalutamide—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	5.31e-05	0.00169	CbGpPWpGaD
Bicalutamide—Cough—Methotrexate—urinary bladder cancer	5.31e-05	0.00045	CcSEcCtD
Bicalutamide—Mental disorder—Doxorubicin—urinary bladder cancer	5.3e-05	0.000449	CcSEcCtD
Bicalutamide—Vomiting—Etoposide—urinary bladder cancer	5.27e-05	0.000446	CcSEcCtD
Bicalutamide—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	5.27e-05	0.00167	CbGpPWpGaD
Bicalutamide—Malnutrition—Doxorubicin—urinary bladder cancer	5.27e-05	0.000446	CcSEcCtD
Bicalutamide—Anaemia—Epirubicin—urinary bladder cancer	5.26e-05	0.000446	CcSEcCtD
Bicalutamide—Rash—Etoposide—urinary bladder cancer	5.22e-05	0.000443	CcSEcCtD
Bicalutamide—Dermatitis—Etoposide—urinary bladder cancer	5.22e-05	0.000442	CcSEcCtD
Bicalutamide—AR—Generic Transcription Pathway—ESR2—urinary bladder cancer	5.21e-05	0.00165	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	5.21e-05	0.00165	CbGpPWpGaD
Bicalutamide—Headache—Etoposide—urinary bladder cancer	5.19e-05	0.00044	CcSEcCtD
Bicalutamide—Flatulence—Doxorubicin—urinary bladder cancer	5.19e-05	0.00044	CcSEcCtD
Bicalutamide—Myalgia—Methotrexate—urinary bladder cancer	5.18e-05	0.000439	CcSEcCtD
Bicalutamide—Chest pain—Methotrexate—urinary bladder cancer	5.18e-05	0.000439	CcSEcCtD
Bicalutamide—Tension—Doxorubicin—urinary bladder cancer	5.17e-05	0.000438	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	5.14e-05	0.000436	CcSEcCtD
Bicalutamide—Nervousness—Doxorubicin—urinary bladder cancer	5.11e-05	0.000433	CcSEcCtD
Bicalutamide—Syncope—Epirubicin—urinary bladder cancer	5.1e-05	0.000432	CcSEcCtD
Bicalutamide—Back pain—Doxorubicin—urinary bladder cancer	5.09e-05	0.000432	CcSEcCtD
Bicalutamide—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	5.08e-05	0.00161	CbGpPWpGaD
Bicalutamide—Muscle spasms—Doxorubicin—urinary bladder cancer	5.06e-05	0.000429	CcSEcCtD
Bicalutamide—Confusional state—Methotrexate—urinary bladder cancer	5e-05	0.000424	CcSEcCtD
Bicalutamide—Loss of consciousness—Epirubicin—urinary bladder cancer	5e-05	0.000424	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CCND1—urinary bladder cancer	4.98e-05	0.00158	CbGpPWpGaD
Bicalutamide—Cough—Epirubicin—urinary bladder cancer	4.97e-05	0.000421	CcSEcCtD
Bicalutamide—Infection—Methotrexate—urinary bladder cancer	4.93e-05	0.000418	CcSEcCtD
Bicalutamide—Nausea—Etoposide—urinary bladder cancer	4.92e-05	0.000417	CcSEcCtD
Bicalutamide—Hypertension—Epirubicin—urinary bladder cancer	4.91e-05	0.000416	CcSEcCtD
Bicalutamide—Nervous system disorder—Methotrexate—urinary bladder cancer	4.87e-05	0.000412	CcSEcCtD
Bicalutamide—Anaemia—Doxorubicin—urinary bladder cancer	4.87e-05	0.000412	CcSEcCtD
Bicalutamide—Thrombocytopenia—Methotrexate—urinary bladder cancer	4.86e-05	0.000412	CcSEcCtD
Bicalutamide—Myalgia—Epirubicin—urinary bladder cancer	4.84e-05	0.000411	CcSEcCtD
Bicalutamide—Chest pain—Epirubicin—urinary bladder cancer	4.84e-05	0.000411	CcSEcCtD
Bicalutamide—Anxiety—Epirubicin—urinary bladder cancer	4.83e-05	0.000409	CcSEcCtD
Bicalutamide—Skin disorder—Methotrexate—urinary bladder cancer	4.82e-05	0.000408	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	4.81e-05	0.000408	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—PTEN—urinary bladder cancer	4.81e-05	0.00153	CbGpPWpGaD
Bicalutamide—Hyperhidrosis—Methotrexate—urinary bladder cancer	4.8e-05	0.000407	CcSEcCtD
Bicalutamide—Dry mouth—Epirubicin—urinary bladder cancer	4.74e-05	0.000402	CcSEcCtD
Bicalutamide—Anorexia—Methotrexate—urinary bladder cancer	4.73e-05	0.000401	CcSEcCtD
Bicalutamide—Syncope—Doxorubicin—urinary bladder cancer	4.72e-05	0.0004	CcSEcCtD
Bicalutamide—Confusional state—Epirubicin—urinary bladder cancer	4.68e-05	0.000397	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	4.67e-05	0.00148	CbGpPWpGaD
Bicalutamide—Oedema—Epirubicin—urinary bladder cancer	4.64e-05	0.000394	CcSEcCtD
Bicalutamide—Loss of consciousness—Doxorubicin—urinary bladder cancer	4.63e-05	0.000392	CcSEcCtD
Bicalutamide—Infection—Epirubicin—urinary bladder cancer	4.61e-05	0.000391	CcSEcCtD
Bicalutamide—Cough—Doxorubicin—urinary bladder cancer	4.59e-05	0.000389	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	4.58e-05	0.00146	CbGpPWpGaD
Bicalutamide—Shock—Epirubicin—urinary bladder cancer	4.57e-05	0.000387	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	4.57e-05	0.00145	CbGpPWpGaD
Bicalutamide—Nervous system disorder—Epirubicin—urinary bladder cancer	4.55e-05	0.000386	CcSEcCtD
Bicalutamide—Thrombocytopenia—Epirubicin—urinary bladder cancer	4.55e-05	0.000385	CcSEcCtD
Bicalutamide—Hypertension—Doxorubicin—urinary bladder cancer	4.55e-05	0.000385	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	4.52e-05	0.000383	CcSEcCtD
Bicalutamide—Skin disorder—Epirubicin—urinary bladder cancer	4.51e-05	0.000382	CcSEcCtD
Bicalutamide—Hyperhidrosis—Epirubicin—urinary bladder cancer	4.49e-05	0.00038	CcSEcCtD
Bicalutamide—Insomnia—Methotrexate—urinary bladder cancer	4.49e-05	0.00038	CcSEcCtD
Bicalutamide—Chest pain—Doxorubicin—urinary bladder cancer	4.48e-05	0.00038	CcSEcCtD
Bicalutamide—Myalgia—Doxorubicin—urinary bladder cancer	4.48e-05	0.00038	CcSEcCtD
Bicalutamide—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	4.48e-05	0.00142	CbGpPWpGaD
Bicalutamide—Anxiety—Doxorubicin—urinary bladder cancer	4.47e-05	0.000379	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	4.47e-05	0.00142	CbGpPWpGaD
Bicalutamide—Paraesthesia—Methotrexate—urinary bladder cancer	4.46e-05	0.000378	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	4.45e-05	0.000377	CcSEcCtD
Bicalutamide—Anorexia—Epirubicin—urinary bladder cancer	4.43e-05	0.000375	CcSEcCtD
Bicalutamide—Dyspnoea—Methotrexate—urinary bladder cancer	4.42e-05	0.000375	CcSEcCtD
Bicalutamide—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	4.42e-05	0.0014	CbGpPWpGaD
Bicalutamide—Somnolence—Methotrexate—urinary bladder cancer	4.41e-05	0.000374	CcSEcCtD
Bicalutamide—Dry mouth—Doxorubicin—urinary bladder cancer	4.38e-05	0.000372	CcSEcCtD
Bicalutamide—Dyspepsia—Methotrexate—urinary bladder cancer	4.37e-05	0.00037	CcSEcCtD
Bicalutamide—Confusional state—Doxorubicin—urinary bladder cancer	4.33e-05	0.000367	CcSEcCtD
Bicalutamide—Decreased appetite—Methotrexate—urinary bladder cancer	4.31e-05	0.000366	CcSEcCtD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	4.3e-05	0.00136	CbGpPWpGaD
Bicalutamide—Oedema—Doxorubicin—urinary bladder cancer	4.3e-05	0.000364	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	4.28e-05	0.000363	CcSEcCtD
Bicalutamide—Fatigue—Methotrexate—urinary bladder cancer	4.28e-05	0.000363	CcSEcCtD
Bicalutamide—Infection—Doxorubicin—urinary bladder cancer	4.27e-05	0.000362	CcSEcCtD
Bicalutamide—Pain—Methotrexate—urinary bladder cancer	4.24e-05	0.00036	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	4.23e-05	0.000359	CcSEcCtD
Bicalutamide—Shock—Doxorubicin—urinary bladder cancer	4.23e-05	0.000358	CcSEcCtD
Bicalutamide—Nervous system disorder—Doxorubicin—urinary bladder cancer	4.21e-05	0.000357	CcSEcCtD
Bicalutamide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	4.21e-05	0.000357	CcSEcCtD
Bicalutamide—Insomnia—Epirubicin—urinary bladder cancer	4.2e-05	0.000356	CcSEcCtD
Bicalutamide—Skin disorder—Doxorubicin—urinary bladder cancer	4.17e-05	0.000354	CcSEcCtD
Bicalutamide—Paraesthesia—Epirubicin—urinary bladder cancer	4.17e-05	0.000353	CcSEcCtD
Bicalutamide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	4.15e-05	0.000352	CcSEcCtD
Bicalutamide—Dyspnoea—Epirubicin—urinary bladder cancer	4.14e-05	0.000351	CcSEcCtD
Bicalutamide—Somnolence—Epirubicin—urinary bladder cancer	4.13e-05	0.00035	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.13e-05	0.00131	CbGpPWpGaD
Bicalutamide—Anorexia—Doxorubicin—urinary bladder cancer	4.1e-05	0.000347	CcSEcCtD
Bicalutamide—Feeling abnormal—Methotrexate—urinary bladder cancer	4.09e-05	0.000347	CcSEcCtD
Bicalutamide—Dyspepsia—Epirubicin—urinary bladder cancer	4.09e-05	0.000346	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	4.06e-05	0.000344	CcSEcCtD
Bicalutamide—Decreased appetite—Epirubicin—urinary bladder cancer	4.04e-05	0.000342	CcSEcCtD
Bicalutamide—AR—Generic Transcription Pathway—NCOR1—urinary bladder cancer	4.02e-05	0.00128	CbGpPWpGaD
Bicalutamide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	4.01e-05	0.00034	CcSEcCtD
Bicalutamide—Fatigue—Epirubicin—urinary bladder cancer	4e-05	0.000339	CcSEcCtD
Bicalutamide—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	4e-05	0.00127	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	3.99e-05	0.00127	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.99e-05	0.00127	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.98e-05	0.00126	CbGpPWpGaD
Bicalutamide—Pain—Epirubicin—urinary bladder cancer	3.97e-05	0.000337	CcSEcCtD
Bicalutamide—Constipation—Epirubicin—urinary bladder cancer	3.97e-05	0.000337	CcSEcCtD
Bicalutamide—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.95e-05	0.00125	CbGpPWpGaD
Bicalutamide—Urticaria—Methotrexate—urinary bladder cancer	3.94e-05	0.000334	CcSEcCtD
Bicalutamide—Body temperature increased—Methotrexate—urinary bladder cancer	3.92e-05	0.000332	CcSEcCtD
Bicalutamide—Abdominal pain—Methotrexate—urinary bladder cancer	3.92e-05	0.000332	CcSEcCtD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	3.92e-05	0.00124	CbGpPWpGaD
Bicalutamide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	3.92e-05	0.000332	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	3.91e-05	0.00124	CbGpPWpGaD
Bicalutamide—Insomnia—Doxorubicin—urinary bladder cancer	3.89e-05	0.000329	CcSEcCtD
Bicalutamide—Paraesthesia—Doxorubicin—urinary bladder cancer	3.86e-05	0.000327	CcSEcCtD
Bicalutamide—Dyspnoea—Doxorubicin—urinary bladder cancer	3.83e-05	0.000325	CcSEcCtD
Bicalutamide—Feeling abnormal—Epirubicin—urinary bladder cancer	3.83e-05	0.000324	CcSEcCtD
Bicalutamide—Somnolence—Doxorubicin—urinary bladder cancer	3.82e-05	0.000324	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.8e-05	0.00121	CbGpPWpGaD
Bicalutamide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	3.8e-05	0.000322	CcSEcCtD
Bicalutamide—Dyspepsia—Doxorubicin—urinary bladder cancer	3.78e-05	0.000321	CcSEcCtD
Bicalutamide—Decreased appetite—Doxorubicin—urinary bladder cancer	3.74e-05	0.000317	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	3.71e-05	0.000314	CcSEcCtD
Bicalutamide—Fatigue—Doxorubicin—urinary bladder cancer	3.71e-05	0.000314	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.69e-05	0.00117	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	3.69e-05	0.00117	CbGpPWpGaD
Bicalutamide—Urticaria—Epirubicin—urinary bladder cancer	3.69e-05	0.000313	CcSEcCtD
Bicalutamide—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	3.68e-05	0.00117	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	3.68e-05	0.00117	CbGpPWpGaD
Bicalutamide—Pain—Doxorubicin—urinary bladder cancer	3.67e-05	0.000311	CcSEcCtD
Bicalutamide—Constipation—Doxorubicin—urinary bladder cancer	3.67e-05	0.000311	CcSEcCtD
Bicalutamide—Abdominal pain—Epirubicin—urinary bladder cancer	3.67e-05	0.000311	CcSEcCtD
Bicalutamide—Body temperature increased—Epirubicin—urinary bladder cancer	3.67e-05	0.000311	CcSEcCtD
Bicalutamide—Hypersensitivity—Methotrexate—urinary bladder cancer	3.66e-05	0.00031	CcSEcCtD
Bicalutamide—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	3.65e-05	0.00116	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.63e-05	0.00115	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.63e-05	0.00115	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	3.63e-05	0.00115	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.6e-05	0.00114	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	3.58e-05	0.00114	CbGpPWpGaD
Bicalutamide—Asthenia—Methotrexate—urinary bladder cancer	3.56e-05	0.000302	CcSEcCtD
Bicalutamide—Feeling abnormal—Doxorubicin—urinary bladder cancer	3.54e-05	0.0003	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	3.51e-05	0.000298	CcSEcCtD
Bicalutamide—Pruritus—Methotrexate—urinary bladder cancer	3.51e-05	0.000298	CcSEcCtD
Bicalutamide—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	3.47e-05	0.0011	CbGpPWpGaD
Bicalutamide—Hypersensitivity—Epirubicin—urinary bladder cancer	3.42e-05	0.00029	CcSEcCtD
Bicalutamide—Urticaria—Doxorubicin—urinary bladder cancer	3.41e-05	0.000289	CcSEcCtD
Bicalutamide—Body temperature increased—Doxorubicin—urinary bladder cancer	3.4e-05	0.000288	CcSEcCtD
Bicalutamide—Abdominal pain—Doxorubicin—urinary bladder cancer	3.4e-05	0.000288	CcSEcCtD
Bicalutamide—Diarrhoea—Methotrexate—urinary bladder cancer	3.4e-05	0.000288	CcSEcCtD
Bicalutamide—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	3.38e-05	0.00107	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	3.35e-05	0.00106	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.34e-05	0.00106	CbGpPWpGaD
Bicalutamide—Asthenia—Epirubicin—urinary bladder cancer	3.33e-05	0.000282	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.31e-05	0.00105	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.31e-05	0.00105	CbGpPWpGaD
Bicalutamide—Pruritus—Epirubicin—urinary bladder cancer	3.29e-05	0.000278	CcSEcCtD
Bicalutamide—Dizziness—Methotrexate—urinary bladder cancer	3.28e-05	0.000278	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	3.28e-05	0.00104	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.24e-05	0.00103	CbGpPWpGaD
Bicalutamide—Diarrhoea—Epirubicin—urinary bladder cancer	3.18e-05	0.000269	CcSEcCtD
Bicalutamide—Hypersensitivity—Doxorubicin—urinary bladder cancer	3.17e-05	0.000268	CcSEcCtD
Bicalutamide—AR—Generic Transcription Pathway—ESR1—urinary bladder cancer	3.16e-05	0.001	CbGpPWpGaD
Bicalutamide—Vomiting—Methotrexate—urinary bladder cancer	3.16e-05	0.000267	CcSEcCtD
Bicalutamide—Rash—Methotrexate—urinary bladder cancer	3.13e-05	0.000265	CcSEcCtD
Bicalutamide—Dermatitis—Methotrexate—urinary bladder cancer	3.13e-05	0.000265	CcSEcCtD
Bicalutamide—Headache—Methotrexate—urinary bladder cancer	3.11e-05	0.000263	CcSEcCtD
Bicalutamide—Asthenia—Doxorubicin—urinary bladder cancer	3.08e-05	0.000261	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.08e-05	0.000979	CbGpPWpGaD
Bicalutamide—Dizziness—Epirubicin—urinary bladder cancer	3.07e-05	0.00026	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.06e-05	0.000971	CbGpPWpGaD
Bicalutamide—Pruritus—Doxorubicin—urinary bladder cancer	3.04e-05	0.000258	CcSEcCtD
Bicalutamide—Vomiting—Epirubicin—urinary bladder cancer	2.95e-05	0.00025	CcSEcCtD
Bicalutamide—Nausea—Methotrexate—urinary bladder cancer	2.95e-05	0.00025	CcSEcCtD
Bicalutamide—Diarrhoea—Doxorubicin—urinary bladder cancer	2.94e-05	0.000249	CcSEcCtD
Bicalutamide—Rash—Epirubicin—urinary bladder cancer	2.93e-05	0.000248	CcSEcCtD
Bicalutamide—Dermatitis—Epirubicin—urinary bladder cancer	2.93e-05	0.000248	CcSEcCtD
Bicalutamide—Headache—Epirubicin—urinary bladder cancer	2.91e-05	0.000247	CcSEcCtD
Bicalutamide—AR—Generic Transcription Pathway—PPARG—urinary bladder cancer	2.88e-05	0.000916	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—SMC1A—urinary bladder cancer	2.88e-05	0.000914	CbGpPWpGaD
Bicalutamide—Dizziness—Doxorubicin—urinary bladder cancer	2.84e-05	0.000241	CcSEcCtD
Bicalutamide—AR—Generic Transcription Pathway—CREBBP—urinary bladder cancer	2.77e-05	0.00088	CbGpPWpGaD
Bicalutamide—Nausea—Epirubicin—urinary bladder cancer	2.76e-05	0.000234	CcSEcCtD
Bicalutamide—Vomiting—Doxorubicin—urinary bladder cancer	2.73e-05	0.000232	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.72e-05	0.000863	CbGpPWpGaD
Bicalutamide—Rash—Doxorubicin—urinary bladder cancer	2.71e-05	0.00023	CcSEcCtD
Bicalutamide—Dermatitis—Doxorubicin—urinary bladder cancer	2.71e-05	0.000229	CcSEcCtD
Bicalutamide—Headache—Doxorubicin—urinary bladder cancer	2.69e-05	0.000228	CcSEcCtD
Bicalutamide—Nausea—Doxorubicin—urinary bladder cancer	2.55e-05	0.000216	CcSEcCtD
Bicalutamide—AR—Gene Expression—ESR2—urinary bladder cancer	2.51e-05	0.000797	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	2.45e-05	0.000779	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	2.41e-05	0.000764	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.37e-05	0.000754	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	2.32e-05	0.000738	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NAT1—urinary bladder cancer	2.32e-05	0.000738	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.29e-05	0.000726	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	2.26e-05	0.000716	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	2.24e-05	0.00071	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	2.21e-05	0.000702	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.18e-05	0.000693	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	2.14e-05	0.000679	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NAT1—urinary bladder cancer	2.14e-05	0.000679	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	2.13e-05	0.000675	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	2.12e-05	0.000673	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NAT1—urinary bladder cancer	2.12e-05	0.000673	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.08e-05	0.000662	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	1.96e-05	0.000621	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	1.94e-05	0.000615	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—NCOR1—urinary bladder cancer	1.94e-05	0.000615	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	1.91e-05	0.000608	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—ERCC2—urinary bladder cancer	1.82e-05	0.000578	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	1.81e-05	0.000574	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	1.76e-05	0.000559	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	1.76e-05	0.000559	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	1.75e-05	0.000554	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	1.66e-05	0.000528	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	1.65e-05	0.000523	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—MYC—urinary bladder cancer	1.64e-05	0.000522	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	1.62e-05	0.000514	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	1.61e-05	0.00051	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—ESR1—urinary bladder cancer	1.52e-05	0.000483	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.47e-05	0.000468	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.41e-05	0.000448	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—TYMP—urinary bladder cancer	1.41e-05	0.000447	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.4e-05	0.000444	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.4e-05	0.000444	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PPARG—urinary bladder cancer	1.39e-05	0.000441	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.35e-05	0.000429	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—CREBBP—urinary bladder cancer	1.33e-05	0.000423	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—TYMP—urinary bladder cancer	1.3e-05	0.000411	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.29e-05	0.000409	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—TYMP—urinary bladder cancer	1.28e-05	0.000408	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.28e-05	0.000406	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NAT2—urinary bladder cancer	1.27e-05	0.000404	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.23e-05	0.000392	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.17e-05	0.000372	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.16e-05	0.000369	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.15e-05	0.000365	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—RRM2—urinary bladder cancer	1.1e-05	0.000349	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.09e-05	0.000345	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.06e-05	0.000336	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ENO2—urinary bladder cancer	1.02e-05	0.000323	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	1.02e-05	0.000323	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.01e-05	0.000321	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.01e-05	0.000321	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1e-05	0.000318	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	9.88e-06	0.000314	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.73e-06	0.000309	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	9.37e-06	0.000297	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ENO2—urinary bladder cancer	9.37e-06	0.000297	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	9.29e-06	0.000295	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ENO2—urinary bladder cancer	9.29e-06	0.000295	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.23e-06	0.000293	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	9.08e-06	0.000288	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	9.01e-06	0.000286	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.87e-06	0.000282	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—TYMP—urinary bladder cancer	8.47e-06	0.000269	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NQO1—urinary bladder cancer	8.21e-06	0.000261	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.96e-06	0.000253	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—MYC—urinary bladder cancer	7.92e-06	0.000251	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NAT2—urinary bladder cancer	7.66e-06	0.000243	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NQO1—urinary bladder cancer	7.55e-06	0.00024	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NQO1—urinary bladder cancer	7.48e-06	0.000238	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.26e-06	0.000231	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.95e-06	0.00022	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	6.85e-06	0.000217	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.62e-06	0.00021	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—RRM2—urinary bladder cancer	6.61e-06	0.00021	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—TYMS—urinary bladder cancer	6.36e-06	0.000202	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.33e-06	0.000201	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	6.3e-06	0.0002	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	6.29e-06	0.0002	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	6.29e-06	0.0002	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	6.24e-06	0.000198	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ENO2—urinary bladder cancer	6.12e-06	0.000194	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	6.12e-06	0.000194	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.04e-06	0.000192	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GPX1—urinary bladder cancer	6.02e-06	0.000191	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	5.94e-06	0.000189	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	5.91e-06	0.000188	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—TYMS—urinary bladder cancer	5.85e-06	0.000186	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—TYMS—urinary bladder cancer	5.8e-06	0.000184	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	5.79e-06	0.000184	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	5.79e-06	0.000184	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	5.74e-06	0.000182	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	5.74e-06	0.000182	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	5.56e-06	0.000177	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GPX1—urinary bladder cancer	5.54e-06	0.000176	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GPX1—urinary bladder cancer	5.49e-06	0.000174	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	5.44e-06	0.000173	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	5.39e-06	0.000171	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	5.11e-06	0.000162	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	5.07e-06	0.000161	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NQO1—urinary bladder cancer	4.94e-06	0.000157	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PPARG—urinary bladder cancer	4.51e-06	0.000143	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	4.33e-06	0.000137	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PPARG—urinary bladder cancer	4.15e-06	0.000132	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	4.12e-06	0.000131	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PPARG—urinary bladder cancer	4.11e-06	0.000131	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	3.98e-06	0.000126	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	3.95e-06	0.000125	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.83e-06	0.000122	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	3.78e-06	0.00012	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	3.78e-06	0.00012	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.62e-06	0.000115	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3.56e-06	0.000113	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	3.55e-06	0.000113	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.34e-06	0.000106	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	3.26e-06	0.000104	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	3.23e-06	0.000103	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PTEN—urinary bladder cancer	3.09e-06	9.82e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—EP300—urinary bladder cancer	2.95e-06	9.36e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.84e-06	9.03e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PTEN—urinary bladder cancer	2.82e-06	8.95e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.71e-06	8.61e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.71e-06	8.61e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.69e-06	8.54e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.6e-06	8.27e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.13e-06	6.77e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.86e-06	5.9e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.77e-06	5.63e-05	CbGpPWpGaD
